

Curriculum Vitae

Name: Samuel T. Wilkinson, MD

School: Yale School of Medicine

Education/Training:

Fellowship Yale School of Medicine, Department of Psychiatry 2017
Residency Yale School of Medicine, Department of Psychiatry 2016
M.D. Johns Hopkins School of Medicine 2012
B.S. Brigham Young University (Mechanical Engineering, *Summa Cum Laude*) 2008

Career/Academic Appointments:

2012-13 Intern, Internal Medicine/Psychiatry, Yale School of Medicine, New Haven, CT
2013-16 Psychiatry Resident/Chief Resident (Interventional Psychiatry), Yale School of Medicine, New Haven, CT
2016-17 Research Fellow, Functional Disability Interventions, Yale School of Medicine, New Haven, CT
2017-2018 Clinician, Yale School of Medicine, New Haven, CT
2018-2023 Assistant Professor, Yale School of Medicine
2023-current Associate Professor

Administrative Positions:

2017-2020 Assistant Director, Yale Depression Research Program
2020-current Associate Director, Yale Depression Research Program

Board Certification/Eligibility

Board Certified, Psychiatry, American Board of Psychiatry & Neurology, 2016

Professional Honors & Recognitions

International/National/Regional

2021: American Foundation for Suicide Prevention, Young Investigator Travel Award
2020: Top 10 Leading Research Achievements, Brain and Behavior Research Foundation
2020: Health Services Research Award, Early Career Scholar, APA
2020: Advanced Research Institute in Mental Health and Aging Scholar Award
2019: New Investigator Award, International Society for CNS Clinical Trials Methodology
2018: Career Development Institute of Psychiatry, Mentoring Award (Deferred until 2019)
2018: Anxiety and Depression Associations of America, Career Development Leadership Program Award
2017: Brain and Behavior Research Foundation (formerly NARSAD), Top Advancements & Breakthroughs for 2017
2017: American Society of Clinical Psychopharmacology, New Investigator Award
2016: American College of Neuropsychopharmacology, Travel Fellowship
2016: Society for Biological Psychiatry, Chairman's Choice Award
2015: New England Journal of Medicine, Journal Watch, Top 10 Psychiatry Papers for 2015

- 2015: American Society of Clinical Psychopharmacology, Fellowship Travel Award
- 2015: American Psychiatric Association, Junior Investigator Research Colloquium Award
- 2014: American Academy of Addiction Psychiatry, Early Career Psychiatry Research Award
- 2014: American Psychiatric Foundation/Janssen, Resident Research Scholar Fellowship Award
- 2005: Tau Beta Pi Engineering Honor Society (Junior Induction)

University

- 2017: Seymour Lustman Award (2nd place) – Yale Department of Psychiatry
- 2015: Seymour Lustman Award (2nd place) – Yale Department of Psychiatry
- 2014: Thomas Detre Research Award – Yale Department of Psychiatry
- 2012: Samuel Novey Prize in Psychological Medicine – Johns Hopkins School of Medicine
- 2009: William Walker Research Award – Johns Hopkins School of Medicine
- 2008: Graduation with University Honors, Brigham Young University
- 2008: Edwin S. Hinckley Scholar, Brigham Young University,
- 2001/4-7: National Merit Scholar, Brigham Young University
- 2001/4-7: Robert C. Byrd Scholar, Brigham Young University

Current Grants/Funding/Projects:

Active

Agency: Patient Centered Outcomes Research Institute (Funded)
Grant number pending
Title: Comparative effectiveness of racemic ketamine versus S-ketamine (Spravato) for depression
PI: Samuel Wilkinson (contact), MPI: Gerard Sanacora
Project period: 03/01/2024-11/30/2029
Total costs for project period: \$12,684,406 (of which \$2,753,814 are indirect costs)

Agency: National Institute of Mental Health
R01MH131528
Title: Examining Intensive Outpatient Programs as a Potential Mechanism to Reduce Suicide Risk During the Post-Hospitalization Period Among Medicaid Recipients
PI: Samuel Wilkinson, contact (MPI: Greg Rhee)
Project period: 09/11/2023-07/31/2028
Total costs for project period: \$2,997,218 (of which \$1,001,391 are indirect costs)

Agency: National Institute of Mental Health
R01MH125205
Title: A feasibility trial of esketamine plus cognitive behavioral therapy for patients with major depressive disorder who are hospitalized for suicidal ideation
PI: Samuel Wilkinson
Project period: 9/15/2020-8/31/2024
Total costs for project period: \$2,434,699 (of which \$765,758 are indirect costs)

Agency: National Institute of Mental Health

R01MH125205-02S1

Title: A feasibility trial of esketamine plus cognitive behavioral therapy for patients with major depressive disorder who are hospitalized for suicidal ideation

PI: Samuel Wilkinson

Project period: 3/15/2022-8/31/2024

Total costs for project period: \$824,725 (of which \$223,001 are indirect costs)

Agency: National Institute of Mental Health

R42MH123357

Title: An Efficacy Trial of a Digital Therapeutic for Suicide Prevention

PI: Patricia Simon, Seth Feuerstein

Role: Co-investigator

Project Period: July 23, 2020 – July 31, 2024

Total costs for project period (Yale site only): \$407,840 (of which \$94,240 are indirect costs)

Agency: National Institute of Drug Abuse

R21DA057540

Role: MPI (contact PI Rajiv Radhakrishnan)

Title: Impact of cannabis legalization on prescription drug use and health outcomes in Connecticut

Project Period: April 1, 2023 – March 31, 2025

Total costs for project period: \$475,440 (of which \$210,236 are indirect costs)

Agency: National Institute of Aging

R01AG080647

Role: Co-investigator (PI Rhee)

Title: Longitudinal Associations of Electroconvulsive Therapy with Neuropsychiatric Symptoms, Geriatric Syndromes, and Nursing Home Admission and Mortality Rates among Community-dwelling Adults with Dementia

Project Period: 07/01/2023 – 06/30/2028

Total costs for project period (Yale subaward): \$244,519 (of which \$98,537 are indirect costs)

Grants Pending

Agency: National Institute of Mental Health

K24MH130587

Title: Patient-Oriented Research, Mentorship, and Training in Interventional Psychiatry Approaches to the Treatment of Individuals with Mood Disorders and Suicidal Ideation

PI: Samuel Wilkinson

Project period: 04/01/2024 – 03/31/2029

Total costs for project period: \$1,016,709 (of which \$75,312 are indirect costs)

Past Grants/Funding/Projects:

Agency: Patient Centered Outcomes Research Institute (PCORI)

NCT03113968

Overall PI: A Anand (Cleveland Clinic)
Yale Site PI: G Sanacora
Role: Co-investigator
Title: Electroconvulsive Therapy versus Ketamine for Severe Resistant Depression
Project period: April 2017 – September 2022
Total costs for project period (all sites): \$1,071,646 (of which \$306,184 are indirect costs)

Agency: National Institute of Mental Health
R21MH117438-02S1
Title: Association of electroconvulsive therapy with health outcomes in older adults with co-occurring depression and dementia
PI: Samuel Wilkinson
Project period: 6/30/2020-1/31/2022
Total costs for project period: \$211,986 (of which \$85,427 are indirect costs)

Agency: National Institute of Mental Health
R21MH117438-01A1
Title: Effects of electroconvulsive therapy on suicide in geriatric patients with major depressive disorder: a nationwide cohort study using propensity score matching and instrumental variable analysis
PI: Samuel Wilkinson
Project period: 3/5/2019-1/31/2022
Total costs for project period: \$325,760 (of which \$50,760 are indirect costs)

Agency: National Institute of Mental Health
R43MH123357
A Digital Therapeutic to Advance the Delivery of Effective Interventions for Suicide Prevention
PI: Seth Feuerstein
Role: Co-investigator
Project period: July 23, 2020 – July 22, 2021
Total costs for project period (Yale site only): \$130,605 (of which \$30,180 are indirect costs)

Agency: Sage Therapeutics
Title: A Phase 3, open-label, 1-year study of the safety, tolerability, and need for re-treatment with SAGE-217 in adult subjects with major depressive disorder
Site PI: Samuel Wilkinson
Project period: 3/20/2019 – 2/4/2022
Total costs for project period (Yale site only): \$72,654 (of which \$21,796 are indirect costs)

Agency: Janssen Research & Development, LLC
ID: ESKETINTRD3008

Title: An Open-Label Long-Term Extension Safety Study of Intranasal Esketamine in Treatment-Resistant Depression
Site PI: G Sanacora, MD, PhD
Role on project: co-investigator
Project period: 7/15/17-6/30/2021

Agency: NIH (NIMH)
Contract #: HHSN271201200006I (FAST-MAS)
Title: A Phase 2A Study to Evaluate the Kappa Opioid Receptor as a Target for the Treatment of Mood and Anxiety Spectrum Disorders by Evaluating Whether LY2456302 Engages Key Neural Circuitry Related to the Hedonic Response Trial
Overall PI: A. Krystal, Site PI: G. Sanacora
Role on Project: Study physician
Project period: 8/29/13-4/15/17
Total costs for project period (Yale site only): \$267,136

Agency: Patterson Trust Mentored Clinical Research Awards
NCT03027362
Title: Cognitive behavioral therapy to sustain the antidepressant effects of intravenous ketamine for treatment-resistant depression: a randomized controlled trial
PI: Samuel Wilkinson
Percent effort: 1%
Project period: 1/15/2017-1/15/2019
Total costs for project period: \$89,650

Agency: Brain and Behavioral Research Foundation (formerly NARSAD)
NCT03027362
Title: Cognitive behavioral therapy to sustain the antidepressant effects of intravenous ketamine for treatment-resistant depression: a randomized controlled trial
PI: Samuel Wilkinson
Percent effort: 10%
Project period: 1/15/2017-1/15/2019
Total costs for project period: \$70,000

Agency: American Foundation for Suicide Prevention
Title: Effect of electroconvulsive therapy on suicide attempts in geriatrics patients with depression
PI: Samuel Wilkinson
Percent effort: 10%
Project period: 10/1/2018-9/31/2020
Total costs for project period: \$84,706

Agency: Janssen Research & Development, LLC
Title: Assessing cognitive outcomes among patients treated with ketamine
PI: Samuel Wilkinson (investigator-initiated study)
Project period: 11/26/2019 – 11/25/2020

Total costs for project period: \$34,580 (of which \$13,935 are indirect costs)

Agency: Agency for Healthcare Quality and Research

K12HS023000

Title: Identifying factors associated with quality of care in the treatment of major depressive disorder

PI: Harlan Krumholz (overall PI), Samuel Wilkinson (project PI)

Percent effort: 47%

Project period: 2/1/2018-1/31/2020

Agency: Janssen Research & Development, LLC

ID: ESKETINSUI3001

Title: A study of the efficacy and safety of intranasal esketamine in the rapid reduction of symptoms of major depressive disorder, in adults at imminent risk for suicide

PI (Site): G Sanacora, MD, PhD

Role on project: co-investigator

Percent effort: 1%

Dates: 7/1/17-3/31/19

Agency: Janssen Research & Development, LLC

ID: ESKETINTRD3004

Title: An open-label controlled trial to evaluate the long-term efficacy and safety of intranasal esketamine for the treatment of major depressive disorder

PI: G Sanacora, MD, PhD

Role on project: co-investigator

Project period: 3/18/16 – 8/1/17

Agency: NIH/NIMH

ID#: 5R25 MH07158408 (training grant for research in residency to cover salary support)

P.I.: Robert Malison, MD

Mentor: Gerard Sanacora, MD, PhD

Role on project: trainee

Project period: 8/1/2004-5/31/2018

Agency: NIH/NIMH

ID#: T32MH062994 (training grant for research in residency to cover salary support)

P.I.: Morris Bell, PhD

Mentor: Gerard Sanacora, MD, PhD

Role on project: trainee

Project period: 4/1/2001 – 6/30/2017

Agency: Janssen Research & Development, LLC

ID: ESKETINSUI2001

Title: A double-blind, randomized, placebo controlled study to evaluate the efficacy and safety of intranasal esketamine for the rapid reduction of the symptoms of major

depressive disorder, including suicidal ideation, in subjects assessed to be at imminent risk for suicide

PI: G Sanacora, MD, PhD

Role on project: co-investigator

Project period: 6/18/14-5/12/16

Agency: Thomas Detre Legacy Fund (Non-profit)

NCT02289248

Title: "Cognitive behavioral therapy in prolonging the antidepressant effects of intravenous ketamine"

P.I.: Samuel Wilkinson, MD

Mentors: Gerard Sanacora, MD PhD; Philip Corlett, PhD

Project period: 7/1/2014 – 6/30/2016

Total costs for project period: \$30,000

Agency: American Psychiatric Foundation (non-profit)

Resident Psychiatric Research Scholar Fellowship

NCT02176473

P.I.: Samuel Wilkinson, MD

Mentor: Gerard Sanacora, MD, PhD

Title: "Computerized cognitive behavioral therapy in prolonging the antidepressant effects of electroconvulsive therapy"

Project period: 7/1/2014-6/30/2015

Total costs for project period: \$2,500

Agency: NIH (NIMH)

Contract #: HHSN271201100006I

Title: Rapidly-Acting Treatments for Treatment-Resistant Depression (RAPID), Low-Field Magnetic Stimulation

Overall PI: M. Fava, Site PI: G. Sanacora

Role on Project: Study physician

Project period: 3/21/12-4/11/16

Agency: NIH (NIMH)

Contract #: HHSN271201100006I

Title: Rapidly-Acting Treatments for Treatment-Resistant Depression (RAPID), Double-Blind Placebo-Controlled Proof of Concept (POC) Trial of Ketamine Therapy in Treatment-Resistant Depression (TRD)

Overall PI: M. Fava, Site PI: G. Sanacora

Role on Project: Study physician

Project period: 9/12/13-3/11/16

Invited Speaking Engagements, Presentations & Workshops Not Affiliated With Yale

2023 Electroconvulsive therapy: Effects on Suicide and All-Cause Mortality, symposium at American College of Neuropsychopharmacology Annual Meeting, December 4

- 2023 Emerging Therapeutics in Mood Disorders: Ketamine and Beyond, lecture to Kaiser Permanente Staff/Physicians, Tampa, Florida, September 1
- 2023 How to Make Progress in Suicide Prevention: Designing and Conducting Clinical Trials among High-Risk Patients, Chair of Symposium at American Society of Psychopharmacology Annual Meeting, Miami, Florida, May 30
- 2023 Electroconvulsive therapy: Opportunities and Challenges, Somatic Treatment Community of Practice, Nationwide VA Seminar (zoom), April 12
- 2023 Update on the Treatment Pipeline for Mood Disorders, Computational and Molecular Psychiatry Seminar, University of Iowa (Zoom), April 7
- 2023 From Real World Data to Real World Evidence – Implementation of Regulatory Guidance in Drug Development, Discussant, International Society of CNS Clinical Trials Methodology Annual Meeting, Washington, D.C., February 15
- 2023 Emerging Therapies for Depressive Disorders, University of Texas Health Houston, McGovern Medical School Department of Psychiatry, January 9
- 2022 Emerging Therapies for Depressive Disorders, University of Utah Department of Psychiatry, December 8
- 2022 Cannabis: Effects on Mental Health, Intermountain Healthcare Conference, Salt Lake City (Virtual Presentation), October 27
- 2022 Emerging Therapies for Depressive Disorders, National Alliance of Mental Illness, Connecticut Chapter Annual Conference, October 21
- 2022 Ketamine and CBT: Combining plasticity-enhancing treatments with cognitive and behavioral therapies to improve longer-term outcomes, University of Pittsburgh Clinical Application of Neuroscience Lab (PI Price), August 24
- 2022 Ketamine and Psychotherapy, American Society of Ketamine Physician Annual Conference, June 10
- 2022 Launching a Clinical Research Career and Transitioning to Independence, Advanced Research Institute Grand Rounds, April 19
- 2022 Interventional Psychiatry: Challenges and Opportunities, Grand Rounds, Baylor College of Medicine, March 16
- 2022 Interventional Psychiatry: Opportunities and Challenges, Grand Rounds, University of Alabama-Birmingham, March 15

- 2022 Regulatory Approval and Implementation of Psychoactive Therapies for Psychiatric Disease: Recent Lessons, lecture for Mood and Anxiety Disorder Center, Mt. Sinai School of Medicine, February 11
- 2021 Ketamine, Esketamine, and Emerging Therapies for Mood Disorders, Grand Rounds at State University of New York, Downstate, November 3
- 2021 Effects of Electroconvulsive Therapy (ECT) on All-Cause Mortality and Suicide in Older Adults, Grand Rounds, Advanced Research Institute (virtual)
- 2020 “Advances in Rapid-acting Antidepressants,” Grand Rounds, Western Virginia Psychiatric Hospital, Staunton, Virginia (virtual)
- 2020 “Rapid-acting Antidepressants: From Clinical Trials to Community Practice,” Grand Rounds, Lincoln Hospital, New York City (Bronx) (virtual)
- 2020 “Management of Depression in Primary Care,” University of Kentucky, presentation to Internal/Family Medicine Residents (virtual)
- 2019 “Emerging pipeline of treatments for depression,” oral presentation at Psychiatric Pharmacotherapy Update, University of Texas-Austin.
- 2019 “Ketamine and other emerging treatments for depression,” grand rounds presentation at University of South Alabama College of Medicine, Department of Psychiatry
- 2018 “Emerging Treatments in Depression,” grand rounds presentation at Lincoln Hospital, New York, Department of Psychiatry
- 2018 “Beyond Ketamine: Emerging Treatments in Mood Disorders,” presentation at the American Society of Ketamine Physicians, Austin, TX
- 2018 “Cognitive behavioral therapy may sustain the antidepressant effects of intravenous ketamine in treatment-resistant depression,” oral presentation at the Oxford Ketamine Conference, Oxford, England
- 2017 “Effect of ketamine on suicidal ideation,” oral presentation to the Mood and Anxiety Disorder Program at the Icahn School of Medicine at Mt. Sinai, New York

Peer Reviewed Conference Presentations Given at Meetings Not Affiliated With Yale:

Speaking Engagements, Presentations, Symposia & Workshops Not Affiliated With Yale:
National/International

- 2023 How to Make Progress in Suicide Prevention: Designing and Conducting Clinical Trials among High Risk Patients, Symposium Chair and Presenter, American Society of Clinical Psychopharmacology, Annual Meeting, Miami, May 30

- 2022 Cognitive behavioral therapy to sustain the antidepressant effect of ketamine in treatment-resistant depression, American Society of Clinical Psychopharmacology, Annual Meeting, Scottsdale, Arizona, June 1
- 2021 Association of Electroconvulsive Therapy with Risks of All-Cause Mortality and Suicide in Older Medicare Patients, oral presentation at IASR / AFSP International Summit on Suicide Research
- 2021 Overcoming Barriers to the Implementation of Novel Treatments for Mood Disorders, Symposium at the Annual Conference of the American Society of Clinical Psychopharmacology (Chair)
- 2021 Innovative Treatment Strategies for Treatment Resistant Major Depressive Disorder, Bipolar Disorder and Schizophrenia, Symposium at the Annual Conference of the American Society of Clinical Psychopharmacology (Presenter)
- 2021 Barriers to Electroconvulsive Therapy in the United States, symposium panelist, International Society of ECT and Neurostimulation Annual Conference (virtual)
- 2021 Brain Stimulation and Ketamine, symposium chair, International Society of ECT and Neurostimulation Annual Conference (virtual)
- 2021 Prolonging the effect of ketamine with cognitive behavioral therapy, invited talk at Oxford University Ketamine and Related Compounds International Conference (virtual)
- 2021 Ketamine Treatment in Real World, Clinical Settings. Symposium, Anxiety and Depression Association of America, Annual Meeting (virtual), symposium with Cristina Cusin and Brittany O'Brien
- 2021 Combining CBT and Interventional Psychiatry: Opportunities in Treatment Resistant Depression, Round Table discussion, Anxiety and Depression Association of America, Annual Meeting (virtual), with Rachel Hershenberg, Rude De Raedt, Sabine Schmid, Joseph De Leo, and Rebecca Price
- 2021 APA Annual Meeting, "Provisions for Monitoring Health Outcomes in State Medical Marijuana Laws in the US," poster presentation (co-author with Gagandeep Bhatia), virtual meeting.
- 2020 "Effects of psychotropic medications on suicidal ideation and suicide risk," Fall Update, American Society of Clinical Psychopharmacology (virtual)
- 2019 "Clinical translation of rapid-acting antidepressants," Symposium Chair at World Congress of Biological Psychiatry, Vancouver, Canada.

- 2019 “Emerging treatment for depression: ketamine and beyond,” oral presentation at Anxiety and Depression Association of America Annual Meeting, Chicago.
- 2019 “Strategies to Maintain the Antidepressant Effects of Ketamine: Cognitive Behavioral Therapy and Repeated Dosing,” symposium presentation at Anxiety and Depression Association of America Annual Meeting, Chicago.
- 2019 US Psych Congress Annual Meeting, “Efficacy Rates of Esketamine Nasal Spray Plus an Oral Antidepressant Among Patients Without an Early Response to Treatment,” poster presentation (co-author), San Diego.
- 2019 Society of Biological Psychiatry Annual Meeting, “Expectancy and Ketamine’s Rapid Antidepressant effect: A Meta-Analysis,” poster presentation (co-author), Chicago.
- 2018 “Comparing and contrasting the data on the rapid anti-suicidal effects of ketamine and ECT,” presentation at American Society of Clinical Psychopharmacology, Miami, FL
- 2018 “Leveraging neuroplasticity to sustain the antidepressant effects of intravenous ketamine through cognitive behavioral therapy,” presentation at Career Development Leadership Program, Anxiety and Depression Association of American, Washington, D.C.
- 2018 American College of Neuropsychopharmacology Annual Meeting, Miami, “Examining factors leading to the underutilization of electroconvulsive therapy in the United States.”
- 2017 “The off-label use of ketamine for the treatment of psychiatric disorders,” oral presentation at American Society of Clinical Psychopharmacology, Miami, FL
- 2017 “Cognitive behavioral therapy may sustain the antidepressant effects of intravenous ketamine in treatment-resistant depression,” presentation at University of Texas, Southwestern, Center for Depression Research and Clinical Care, Dallas, TX
- 2016 “GRADEing evidence in psychiatry: the case of medical marijuana for psychiatric indications,” workshop presentation at American Psychiatric Association annual meeting, Atlanta, GA (co-presenters D. Cyril D’Souza and Rajiv Radhakrishnan)
- 2014 “Attitudes towards Marijuana and Its Legalization in a Population of Substance Abusing Patients,” oral presentation at American Academy of Addiction Psychiatry annual meeting, Aventura, FL.
- 2014 “Marijuana Use in PTSD,” oral presentation at American Academy of Addiction Psychiatry annual meeting, Aventura, FL, December 2014
- 2014 American Psychiatric Association Annual Meeting, New York, “Repetitive and compulsive behaviors in a cohort of 63 Down syndrome subjects.”

Regional

- 2019 “Suicide risk assessment in primary care settings,” resident lecture, Bridgeport Hospital, Bridgeport, CT
- 2018 “Emerging treatments in the therapeutic pipeline for mood disorders,” lecture for internists, Lawrence and Memorial Hospital, New London, CT
- 2018 “New developments in our understanding of the pathophysiology and treatment of mood disorders,” resident lecture, Bridgeport Hospital, Bridgeport, CT
- 2018 “Management of Depression in Primary Care,” resident lecture, Greenwich Hospital, Greenwich, CT
- 2018 “Management of Depression in Primary Care with an Emphasis on Suicide Risk Assessment,” resident lecture, Waterbury Hospital, Waterbury, CT
- 2017 “Assessment and Management of Treatment-Resistant Depression”, grand rounds presentation at Bridgeport Hospital, Yale New Haven Health, Bridgeport, CT.
- 2017 “Management of Mood disorders,” grand rounds, St. Mary’s Hospital, Waterbury, CT
- 2017 “Management of Depression in Primary Care,” grand rounds, Waterbury Hospital, Waterbury, CT
- 2017 “Treatment Resistant Depression,” grand rounds, Norwalk Hospital, Norwalk, CT
- 2014 “Substance Use Disorders in Medical Practice,” presentation at American Society of Addiction Medicine, Connecticut State Medical Society Educational Competition, (co-presenter with Rajiv Radhakrishnan).

Professional/Journal Service:

Peer Review Groups/Grant Sections:

Fondazione Cariplo Grant Reviewer (Ad Hoc)

PCORI Foundation Reviewer (Ad Hoc)

PCORI Merit Reviewer (Ad Hoc)

Editorial Board

PLoS One (2018-current)

Journal of Clinical Psychiatry (2022-current)

Ad hoc reviewer

Acta Psychiatrica Scandinavica; American Journal of Preventive Medicine; American Journal of Psychiatry; Annals of Medicine; Biological Psychiatry; Bipolar Disorders; British Journal of Psychiatry; International Journal of Neuropsychopharmacology; JAMA Pediatrics; JAMA Psychiatry; Journal of Affective Disorders; Journal of Clinical Psychiatry; Journal of Clinical Psychopharmacology; Journal of Chronic Stress; Lancet Psychiatry;

Neuropsychopharmacology; New England Journal of Medicine, the Medical Letter; Progress in Neuropsychopharmacology & Biological Psychiatry; Psychiatric Research; Psychology of Addictive Behaviors; Psychopharmacology; Translational Psychiatry

Guest Editor

American Journal of Psychiatry, Residents' Journal, March 2015

Professional Service/Membership for Professional Organizations:

- 2023-current Associate Member, American College of Neuropsychopharmacology
- 2015-current Member, American Society of Clinical Psychopharmacology (formerly NCDEU), Member of Steering Committee – Early Career Committee
- 2015-current Member, Anxiety and Depression Association of America,
- 2014 Member, American Society of Addiction Medicine
- 2012/4-5 Member, American Psychiatric Association,
- 2005-8 Chapter President/Activities Coordinator, Tau Beta Pi Engineering Honor Society

Community/Other Service

- 2008-2012 Boy Scout Mentor/Assistant to Bishop, Church of Jesus Christ of Latter-Day Saints, Baltimore, Maryland
- 2012-current Bishop/Executive Secretary/High Councilor, Church of Jesus Christ of Latter-day Saints, Woodbridge, Connecticut
- 2011-2 Student Preceptor Program, taught clinical skills to 1st year medical students
- 2008-10 Incentive Mentoring Program, served as student mentor to disadvantaged adolescents
- 2006-7 Spanish Translation Assistant, Mountainlands Community Health Center, Utah

Yale University Service

- 2013-2015 Resident Journal Club Leader, Yale School of Medicine

Public Service

- 2019 Invited participant for the United States House of Representatives Committee on Veterans' Affairs roundtable discussion on H.R. 172, VA Medicinal Cannabis Research Act of 2019
- 2019 "Addressing Systemic Issues in The Care Of Depression: Reflections On Ashley Clayton's 'Narrative Matters' Essay," blog post. *Health Affairs Blog*, May 1, 2019. DOI: 10.1377/hblog20190429.716582.
- 2014 "The marijuana industry is following the trail blazed by big tobacco," Op-Ed. *The Washington Post*, December 5, 2014 (print edition Dec 7, 2014).
- 2014 "Smoking out the meaning in Colorado's marijuana law," Letter to the Editor. *The Washington Post*, January 15, 2014
- 2014 "Medical Downsides of Rocky Mountain High." Interview on OpinionJournal on *Wall Street Journal Live*, January 3, 2014: <http://live.wsj.com/video/opinion-medical-downsides-of-rocky-mountain-highs/6662DA1E-49B7-42A2-837A-18D0679A9C14.html#!6662DA1E-49B7-42A2-837A-18D0679A9C14>.
- 2013 "Pot-Smoking and the Schizophrenia Connection," Op-Ed. *Wall Street Journal*. July 2, 2013, page A13.

Bibliography:

Peer-Reviewed Original Research (* denotes first or senior author)

1. **Wilkinson ST***, Stefanovich E, Rosenheck R. Marijuana use is associated with worse outcomes in symptom severity and violent behavior in patients with PTSD. *J Clin Psychiatry*, 2015, 76(9);1174-1180.
2. **Wilkinson ST***, Van Schalkwyk GI, Davidson L, D'Souza DC. The formation of risk perception in a population of substance abusing veterans. *Psychiatr Q*, 2016;87(1):177-87.
3. **Wilkinson ST***, Ostroff RB, Sanacora G. Computer-assisted cognitive behavior therapy to prevent relapse following electroconvulsive therapy. *J ECT*, 2017;33(1):52-57.
4. **Wilkinson ST***, Sanacora G, Bloch MH. Hippocampal volume changes following electroconvulsive therapy: a systematic review and meta-analysis. *Biological Psychiatry: Cognitive Neuroscience and Neuroimaging*, 2017 May;2(4):327-335.
5. **Wilkinson ST***, Rosenheck RA. Electroconvulsive therapy at a Veterans Health Administration Medical Center. *J ECT*, 2017 Dec;33(4):249-252.
6. **Wilkinson ST***, Wright D, Fasula MK, Fenton L, Griep M, Ostroff RB, Sanacora G. Cognitive behavioral therapy may sustain antidepressant effects of intravenous ketamine in treatment-resistant depression. *Psychother Psychosom*, 2017;86(3):162-7.
7. **Wilkinson ST***, Toprak M, Turner MS, Levine SP, Katz RB, Sanacora G. A Survey of the Clinical, Off-Label Use of Ketamine as a Treatment for Psychiatric Disorders. *Am J Psychiatry*, 2017;174(6):695-6.
8. **Wilkinson ST***, Ballard ED, Bloch MH, Mathew SJ, Murrough JW, Feder A, Sos P, Wang G, Zarate CA, Sanacora G. The effect of a single-dose of intravenous ketamine on suicidal ideation: a systematic review and individual participant data meta-analysis. *Am J Psychiatry*, 2018 Feb 1;175(2):150-158.
9. Van Schalkwyk GI, **Wilkinson ST**, Davidson L, Silverman WK, Sanacora G. Acute psychoactive effects of intravenous ketamine during treatment of mood disorders: analysis of the Clinician Administered Dissociative State Scale. *J Affect Dis*, 2018 Feb;227:11-16.
10. **Wilkinson ST***, Agbese E, Leslie DL, Rosenheck RA. Who receives electroconvulsive therapy? Data from privately insured Americans. *Psychiatr Serv*, 2018 May 1;69(5):542-548.
11. **Wilkinson ST***, Katz RB, Toprak M, Webler R, Ostroff RB, Sanacora G. Acute and longer-term outcomes using ketamine as a clinical treatment at the Yale Psychiatric Hospital. *J Clin Psychiatry*, 2018 Jul 24;79(4).
12. **Wilkinson ST***, Kiselycznyk C, Banasr M, Webler RD, Haile C, Mathew SJ. Serum and plasma brain-derived neurotrophic factor and response in a randomized controlled trial of riluzole for treatment resistant depression. *J Affect Dis*, 2018 Dec 1;241:514-518.
13. Fava M, Freeman MP, Flynn M, Judge H, Hoepfner BB, Cusin C, Ionescu DF, Mathew SJ, Chang LC, Iosifescu DV, Murrough JW, Debattista C, Schatzberg AF, Trivedi MH, Jha M, Sanacora G, **Wilkinson ST**, Papakostas GI. Double-Blind, Placebo-Controlled, Dose-Ranging Trial of Intravenous Ketamine as Adjunctive Therapy in Treatment-Resistant Depression (TRD). *Mol Psychiatry*, 2018 Oct 3. [Epub ahead of print]

14. Mathew SJ*, **Wilkinson ST***, Altinay M, Asghar-Ali A, Chang LC, Collins KA, Dale RM, Hu B, Krishnan K, Kellner CH, Malone DA, Murrough JW, Ostroff RB, Sanacora G, Shao M, Anand A. ELectroconvulsive therapy (ECT) vs. Ketamine in patients with Treatment-resistant Depression: the ELEKT-D Study Protocol. *Contemp Clin Trials*, 2019 Feb;77:19-26. **Shared first authorship*.
15. **Wilkinson ST***, Farmer C, Ballard E, Mathew SJ, Grunebaum MF, Murrough JW, Sos P, Wang G, Gueorguieva R, Zarate CA. Impact of midazolam vs. saline on effect size estimates in controlled trials of ketamine as a rapid-acting antidepressant. *Neuropsychopharmacology*, 2019 Jun;44(7):1233-1238.
16. Tsai J, Huang M, **Wilkinson ST**, Edelen C, Rosenheck RA, Holtzheimer PE. A measure to assess perceptions and knowledge about ECT: development and psychometric properties. *J ECT*, 2020 Mar;36(1):e1-e6.
17. Rhee TG, Barry LC, Kuchel GA, Steffens DC, **Wilkinson ST***. Associations of Adverse Childhood Experiences with DSM-5 Psychiatric and Substance Use Disorders in Older Adults. *J Am Geriatr Soc*, 2019 Oct;67(10):2085-2093.
18. Sakurai H, Dording C, Yeung A, Foster S, Jain F, Chang T, Trinh N, Bernard-Negron R, Boyden S, Iqbal S, **Wilkinson ST**, Mathew S, Mischoulon D, Fava M, Cusin C. Longer-term open-label study of adjunctive riluzole in treatment-resistant depression. *J Affect Disord*, 2019 Nov 1;258:102-108.
19. Ochs-Ross R, Daly EJ, Zhang Y, Lane R, Lim P, Morrison RL, Hough D, Manji H, Drevets WC, Sanacora G, Steffens DC, Adler C, McShane R, Gaillard R, **Wilkinson ST**, Singh JB. Efficacy and Safety of Esketamine Nasal Spray Plus an Oral Antidepressant in Elderly Patients with Treatment-Resistant Depression-TRANSFORM-3. *Am J Geriatr Psychiatry*, 2020 Feb;28(2):121-141.
20. Wajs E, Aluisio L, Holder R, Daly E, Lane R, Lim P, George JE, Morrison R, Sanacora G, Young AH, Kasper S, Sulaiman AH, Li C-T, Paik J-W, Manji H, Hough D, Grunfeld J, Jeon HJ, **Wilkinson ST**, Drevets WC, Singh JB. Esketamine Nasal Spray Plus Oral Antidepressant in Patients with Treatment-Resistant Depression: Assessment of Long-term Safety in a Phase 3, Open-label Study (SUSTAIN-2). *J Clin Psychiatry*, 2020 Apr 28;81(3):19m12891.
21. Schmutte T, **Wilkinson ST***. Suicide in Older Adults with and without Known Mental Illness Results from the National Violent Death Reporting System, 2003-2016, *Am J Prev Med*, 2020 Apr;58(4):584-590.
22. Rhee TG, **Wilkinson ST***. Exploring the Psychiatrist-Industry Financial Relationship: Insight from the Open Payment Data of Centers for Medicare and Medicaid Services, *Adm Policy Ment Health*, 2020 Jul;47(4):526-530.
23. Tsai J, Huang M, Rosenheck RA, **Wilkinson S***. A randomized controlled trial of video psychoeducation for electroconvulsive therapy in United States. *Psychiatr Serv*, 2020 Jun 1;71(6):562-569.
24. Rhee TG, Olfson M, Nierenberg AA, **Wilkinson ST***. 20-years trends in the pharmacologic treatment of bipolar disorder by psychiatrists in outpatient care settings. *Am J Psychiatry*, 2020 Aug 1;177(8):706-715.
25. Tsai J, Huang M, **Wilkinson ST**, Edelen C. Effects of video psychoeducation on perceptions and knowledge about electroconvulsive therapy. *Psychiatry Res*, 2020 Feb 3;286:112844.

26. Rhee, TG, Olfson M, **Wilkinson ST***. Changes in Pharmacotherapeutic Approaches in the Treatment of Bipolar Disorder by Primary Care Physicians. *Gen Hosp Psychiatry*, 2020 Nov-Dec;67:141-143.
27. Rhee TG, Olfson M, Sint K, **Wilkinson ST***. Characterization of the Quality of Electroconvulsive Therapy Among Older Medicare Beneficiaries. *J Clin Psychiatry*, 2020 Jul 7;81(4):19m13186.
28. Rhee TG, **Wilkinson ST**, Steffens DC, Rosenheck RA, Olfson M. Increasing Treatment for Depression among US Adults Who Screen Positive for Depression. *JAMA Psychiatry*, 2020 Nov 1;77(11):1193-1195.
29. Srivastava S, Clark B, Landy-Schmitt C, Offermann EA, Kline AD, **Wilkinson ST**, Gardos MA. Repetitive and Self-injurious Behaviors in Children with Cornelia de Lange Syndrome. *J Autism Dev Disord*, 2021 May;51(5):1748-1758.
30. **Wilkinson ST***, Kitay BM, Harper A, Rhee TG, Sint K, Ghosh A, Ortiz Lopez M, Saenz S, Tsai J. Examining barriers to the implementation of electroconvulsive therapy (ECT): results from a nation-wide survey of ECT practitioners. *Psychiatr Serv*, 2021 Jul 1;72(7):752-757.
31. Voelker J, Cai Q, Kuvadia H, Daly E, Connolly N, Pesa J, Sheehan JJ, **Wilkinson ST***. Mental Healthcare Resource Utilization and Barriers to Receiving Mental Health Services Among US Adults with a Major Depressive Episode and Suicidal Ideation or Behavior With Intent. *J Clin Psychiatry*, 2021 Sep 14;82(6):20m13842.
32. **Wilkinson ST***, Rhee TG, Joormann J, Webler R, Ortiz Lopez M, Kitay BM, Fasula M, Fenton L, Sanacora G. Cognitive behavioral therapy to sustain the antidepressant effects of ketamine in treatment-resistant depression: A randomized clinical trial. *Psychother Psychosom*, 2021;90(5):318-327.
33. Turkoz I, Daly E, Singh J, Lin X, Tyymofyeyev T, Williamson D, Salvatore G, Nash AI, Macaluso M, **Wilkinson ST**, Nelson JC. Treatment Response With Esketamine Nasal Spray Plus an Oral Antidepressant in Patients With Treatment-Resistant Depression Without Evidence of Early Response: A Pooled Post Hoc Analysis of the TRANSFORM Studies. *J Clin Psychiatry*, 2021 Jul 20;82(4):20m13800.
34. Voelker J, Kuvadia H, Cai Q, Daly E, Wang K, Pesa J, Connolly N, Sheehan JJ, **Wilkinson ST***. United States National Prevalence and Trends in Prevalence of Major Depressive Episode and Co-occurring Suicidal Ideation and Treatment Resistance Among Adults. *J Affect Dis Reports*, July 1, 2021, Vol 5.
35. Chouairi F, Fuery MA, Caraballo C, Sen S, Maulion C, **Wilkinson ST**, McCullough M, Miller PE, Pacor J, Leifer ES, Felker GM, Valezquez EJ, Fiuzat M, O'Connor CM, Januzzi JL, Desai NR, Ahmad T. The Impact of Depression on Outcomes in Patients with Heart Failure and Reduced Ejection Fraction Treated in the GUIDE-IT Trial. *J Cardiac Failure*, 2021 Dec;27(12):1359-1366.
36. Rhee TG, Sint KJ, Olfson M, Gerhard T, Busch S, **Wilkinson ST***. Association of Electroconvulsive Therapy with Risks of All-Cause Mortality and Suicide in Older Medicare Patients. *Am J Psychiatry*, 2021 Dec;178(12):1089-1097.
37. **Wilkinson ST***, Rhee TG, Tsai J. Utilization of Electroconvulsive Therapy for Older Homeless Adults Covered by Medicare. *Psychiatr Q*. 2021 Sep 1. doi: 10.1007/s11126-021-09946-3.
38. Voelker J, **Wilkinson ST**, Katz EG, Nash AI, Daly E, Ali A, Lovink A, Stahl J, Desai A, Kuvadia H, Neslusan C, Sheehan JJ. A choice-based conjoint analysis of the psychiatrist

- decision-making process used in determining when to discharge adults with major depressive disorder hospitalized for active suicidal ideation with intent. *Journal of Nervous and Mental Disease*, 2021 Dec 22. doi: 10.1097/NMD.0000000000001463. Online ahead of print.
39. **Wilkinson ST***, Trujillo Diaz D, Rupp ZW, Kidambi A, Ramirez KL, Flores JM, Avila-Quintero VJ, Rhee TG, Olfson M, Bloch MH. Pharmacological and Somatic Treatment Effects on Suicide in Adults: A Systematic Review and Meta-analysis. *Depression and Anxiety*, 2021 Nov 11. doi: 10.1002/da.23222. Online ahead of print.
 40. Tsai J, Szymkowiak D, **Wilkinson ST**, Holtzheimer P. Twenty-year trends in use of electroconvulsive therapy among homeless and domiciled veterans with mental illness, *CNS Spectrums*, 2021 Dec 13:1-7. doi: 10.1017/S1092852921001061. Online ahead of print.
 41. Nikayin S, Rhee TG, Cunningham ME, de Fontnouvelle CA, Ostroff RB, Sanacora G, **Wilkinson ST***. Evaluation of the trajectory of depression severity with ketamine and esketamine treatment in a clinical setting. *JAMA Psychiatry*, 2022 Jul 1;79(7):736-738. doi: 10.1001/jamapsychiatry.2022.1074.
 42. Price RB, Kissel N, Baumeister A, Rohac R, Woody ML, Ballard ED, Zarate CA, Deakin W, Abdallah CG, Feder A, Charney DS, Grunebaum MF, Mann JJ, Mathew SJ, Gallagher B, McLoughlin DM, Murrough JW, Muthukumaraswamy S, McMillan R, Sumner R, Papakostas G, Fava M, Hock R, Phillips JL, Blier P, Shiroma P, Šoš P, Su T, Chen M, Tiger M, Lundberg J, **Wilkinson ST**, Wallace ML. International pooled patient-level meta-analysis of ketamine infusion for depression: In search of clinical moderators. *Mol Psychiatry*. 2022 Dec;27(12):5096-5112. doi: 10.1038/s41380-022-01757-7. Epub 2022 Sep 7.
 43. Bloomfield-Clagett B, Ballard ED, Greenstein DK, **Wilkinson ST**, Grunebaum MF, Murrough JW, Mathew SJ, Phillips J, Fava M, Sanacora G, Zarate CA, Jr., A Participant-Level Integrative Data Analysis of Differential Placebo Response for Suicidal Ideation and Non-Suicidal Depressive Symptoms in Clinical Trials of Intravenous Racemic Ketamine. *Int J Neuropsychopharmacology*. 2022 Oct 25;25(10):827-838. doi: 10.1093/ijnp/pyac055.
 44. Rhee TG, Shim SR, Forester BP, Nierenberg AA, McIntyre, RS, Papakostas GI, Krystal JH, Sanacora G, **Wilkinson ST***. Efficacy and Safety of Ketamine versus Electroconvulsive Therapy among Patients with Major Depressive Disorder: A Systematic Review and Meta-Analysis, *JAMA Psychiatry*. 2022 Dec 1;79(12):1162-1172. doi: 10.1001/jamapsychiatry.2022.3352.
 45. **Wilkinson ST***, Rhee TG, Forester B, Rhee TG. Effects of Electroconvulsive Therapy on Functional Outcomes among Medicare Patients with Co-morbid Depression and Dementia: A Nationwide One-year Follow-up Study, *J Clin Psychiatry*. 2023 Jan 25;84(2):22m14583. doi: 10.4088/JCP.22m14583.
 46. Turkoz I, Nelson JC, **Wilkinson ST**, Borentain S, Macaluso M, Trivedi MH, Williamson D, Sheehan JJ, Salvatore G, Singh J, Daly E. Predictors of response and remission in patients with treatment-resistant depression: a post hoc pooled analysis of two acute trials of esketamine nasal spray. *Psychiatry Research*. 2023 May;323:115165. doi: 10.1016/j.psychres.2023.115165. Epub 2023 Mar 16.
 47. Zaki N, Chen L, Lane R, Doherty T, Drevets W, Morrison R, Sanacora G, **Wilkinson ST**, Popova V, Fu DJ. Long-Term Safety and Maintenance of Response with Esketamine

- Nasal Spray in Participants With Treatment-Resistant Depression: Interim Results of the SUSTAIN-3 Study. *Neuropsychopharmacology*. 2023 Jul;48(8):1225-1233. doi: 10.1038/s41386-023-01577-5. Epub 2023.
48. Anand A, Mathew SJ, Sanacora G, Murrrough JW, Goes FS, Altinay M, Aloysi AS, Asghar-Ali AA, Barnett BS, Chang LC, Collins KA, Costi S, Iqbal S, Jha MK, Krishnan K, Malone DA, Nikayin S, Nissen SE, Ostroff RB, Reti IM, **Wilkinson ST**, Wolski K, Hu B. ECT vs. Ketamine for Non-psychotic Treatment-Resistant Major Depression. *New England Journal of Medicine*. 2023 Jun 22;388(25):2315-2325. doi: 10.1056/NEJMoa2302399. Epub 2023 May 24.
49. Palamar JJ, **Wilkinson ST**, Carr TH, Rutherford C, Cottler LB. Investigating the Availability of Illicit Ketamine in the United States: Trends in Ketamine Seizures, 2017-2022. *JAMA Psychiatry*. 2023 Jul 1;80(7):750-751. doi: 10.1001/jamapsychiatry.2023.1423.
50. Castro M, **Wilkinson ST**, Al Jurdi RK, Petrillo MP, Zaki N, Borentain S, Fu DJ, Turkoz I, Sun L, Brown B, Cabrera P. Efficacy and Safety of Esketamine Nasal Spray in Patients With Treatment-Resistant Depression Who Completed a Second Induction Period: Analysis of the Ongoing SUSTAIN-3 Study. *CNS Drugs*. 2023 Aug;37(8):715-723. doi: 10.1007/s40263-023-01026-3.
51. Kitay BM, Murphy E, Macaluso M, Corlett PR, Hershenberg R, Joormann J, Martinez-Kaigi V, Nikayin S, Rhee TG, Sanacora G, Shelton R, Thase ME, **Wilkinson ST**. Cognitive Behavioral Therapy following Esketamine for Major Depression and Suicidal Ideation for Relapse Prevention: the CBT-ENDURE Randomized Clinical Trial Study Protocol. *Psychiatry Research*, in press (accepted).

Chapters, Books, and Reviews

52. **Wilkinson ST**, Yarnell S, Radhakrishnan R, Ball SA, D'Souza DC. Marijuana legalization: impact on public health. Invited review (to Dr. Wilkinson), *Annual Review of Medicine*, 2016;67:453-66.
53. Radhakrishnan R, **Wilkinson ST**, D'Souza DC (shared first authorship). Gone to pot – a review of the association between cannabis and psychosis. *Frontiers in Psychiatry*, May 2014, doi: 10.3389/fpsyt.2014.00054.
54. **Wilkinson ST**, Radhakrishnan R, D'Souza DC. Impact of cannabis use on the development of psychotic disorders. *Current Reports Addiction*, April 2014; 1:115-28.
55. **Wilkinson ST**, Radhakrishnan R, D'Souza DC. Medical marijuana: a systematic review of the evidence for psychiatric indications. *Journal of Clinical Psychiatry*, 2016 Aug; 77(8): 1050-64. doi: 10.4088/JCP.15r10036.
56. **Wilkinson ST**, Sanacora G. Ketamine: a potential rapid-acting anti-suicidal agent? *Depression and Anxiety*, 2016 Aug; 33(8):711-7. doi: 10.1002/da.22498.
57. **Wilkinson ST**, Ostroff RB, Katz RB, Krystal JH. Ketamine: a promising rapid-acting antidepressant. In *Understanding Depression: Contemporary Issues*, ed. Yong-Ku Kim, Springer Nature: 2018.
58. Sanacora G, Kitay BM, **Wilkinson ST**. The search for rapid acting antidepressants: Research synthesis and perspectives. In *Neurobiology of Depression*, ed. Joao de Quevedo, Elsevier, 2019.
59. **Wilkinson ST**, Holtzheimer PE, Gao S, Kirwin DS, Price RB. Leveraging neuroplasticity to enhance adaptive learning: The potential for synergistic somatic-behavioral treatment

- combinations to improve clinical outcomes in depression. *Biol Psychiatry*, 2019 Mar 15;85(6):454-465.
60. **Wilkinson ST**, Sanacora G. A new generation of antidepressants: an update of the pharmaceutical pipeline for novel and rapid-acting therapeutics in mood disorders based on glutamate/GABA neurotransmitter systems. *Drug Discov Today*, 2019 Feb;24(2):606-615.
 61. **Wilkinson ST**, Kitay BM. Ketamine, esketamine, and a new generation of antidepressants. *Psychiatr Ann*, 2020;50(2):54-61.
 62. Davoudian PA, **Wilkinson ST**. Clinical overview of NMDA-R Antagonists and Clinical Practice. In *Advances in Pharmacology*, ed. Ronald Duman and John Krystal, 2020;89:103-129.
 63. Hecking J, Davoudian PA, **Wilkinson ST**. Emerging therapeutics based on the amino acid neurotransmitter system: An update on the pharmaceutical pipeline for mood disorders, *Chronic Stress*, 2021 Jun 2;5:24705470211020446.
 64. Nikayin S, Murphy E, Krystal JH, **Wilkinson ST**. Long-term Safety of Ketamine and Esketamine in Treatment of Depression, *Expert Opinion on Drug Safety*, in press.
 65. **Wilkinson ST**. *Purpose: What Evolution and Human Nature Imply About the Meaning of Our Existence*. Pegasus Books, Forthcoming in 2024.
 66. Rogan T, **Wilkinson ST**. The Role of Psychotherapy in the Management of Treatment-Resistant Depression. *Psychiatr Clin North Am*. 2023 Jun;46(2):349-358. doi: 10.1016/j.psc.2023.02.006. Epub 2023 Mar 15.
 67. Krystal JH, Kaye AP, Jefferson S, Girgenti MJ, **Wilkinson ST**, Sanacora G, Esterlis I. Ketamine and the neurobiology of depression: toward next-generation rapid-acting antidepressant treatments. *Proceedings of the National Academy of Science*, in press (accepted).
 68. Muniza M, **Wilkinson ST**. A Review of Tricyclic Antidepressants and MAO Inhibitors, in American Psychiatric Association Pocket Guide to Practical Psychopharmacology, 1st edition, ed. by Matthew Macaluso and Calley Johnston, American Psychiatric Publishing, Inc., in press (accepted).
 69. Rhee TG, Davoudian P, Sanacora G, **Wilkinson ST**. Psychedelic Renaissance: Revitalized Potential Therapies for Psychiatric Disorders. *Drug Discovery Today*, in press (accepted).

Editorials and Commentaries

70. **Wilkinson ST**. Medical and recreational marijuana: commentary and review of the literature. *Missouri Medicine Journal*, Nov-Dec 2013; 110(6):524-8.
71. **Wilkinson ST**. Reflections on Residency: Pre-Rounding. *Yale Journal of Biology and Medicine*, March 2014; 87(1): 91-92.
72. **Wilkinson ST**, D'Souza DC. Problems with the Medicalization of Marijuana. *JAMA*. June 18, 2014; 311(23): 2377-8.
73. **Wilkinson ST**, Sanacora G. Considerations on the off-label use of ketamine as a treatment for mood disorders. *JAMA*, 2017 Sep 5;318(9):793-794. doi: 10.1001/jama.2017.10697.
74. **Wilkinson ST**, Howard DH, Busch SH. Psychiatric practice patterns and barriers to the adoption of esketamine. *JAMA*, Sep 2019;322(11):1039-1040.

75. Bartoli F, **Wilkinson ST**. Ketamine and esketamine for suicidal ideation: recent progress and practical issues. *Aust N Z J Psychiatry*, 2020 Feb;54(2):206-207.
76. **Wilkinson ST**. Ketamine in the Real World: Where Do We Go From Here? *Journal of Clinical Psychiatry*. 2022 Sep 14;83(6):22com14648. doi: 10.4088/JCP.22com14648.
77. **Wilkinson ST**, Palamar JJ, Sanacora G. The Rapidly Shifting Ketamine Landscape in the United States. *JAMA Psychiatry* (in press).

Case Reports, Technical Notes, Letters

78. **Wilkinson ST**, Grunwald MR, Paik J, Ostrow LW, Gelber AC. Hickam's Dictum and the Rare Convergence of Antisynthetase Syndrome and Hemoglobin SC Disease. *QJM: Monthly Journal of the Association of Physicians*, 2015; 108(9);735-737.
79. **Wilkinson ST**, D'Souza DC. Medicalization of Marijuana – Reply [Letter to the editor]. *JAMA*. Nov 12, 2014;312(18):1931-2.
80. **Wilkinson ST**, Chang SB, Foley T, Lipsey JR, MacKinnon DF. Delirium presenting as mania in a patient with end-stage COPD. *Am J Psychiatry*, Aug 2014;171(8): 821-24.
81. **Wilkinson ST**, Helgeson LE, Ostroff RB. Cerebral aneurysm and ECT. *J ECT*, 2014;30(4):e47-9.
82. Toprak M, **Wilkinson ST**, Ostroff RB. Successful treatment with electroconvulsive therapy of a patient with bipolar disorder and a 7-mm cerebral aneurysm. *J ECT*, 2017 Mar;33(1):e8.
83. Dwyer JB, Beyer C, **Wilkinson ST**, Ostroff RB, Qayyum Z, Bloch MH. Ketamine as a Treatment for Adolescent Depression: A Case Report. *J Am Acad Child Adolesc Psychiatry*. 2017 Apr;56(4):352-354. doi: 10.1016/j.jaac.2017.01.006.
84. **Wilkinson ST**, Sanacora G. Authorship credit for large clinical trials [Letter]. *JAMA*, 2018 Feb 20;319(7):722-723.
85. Kitay BM, Katz RB, **Wilkinson ST**, Ostroff RB. The Successful Use of Electroconvulsive Therapy in a Patient With Cerebral Aneurysms and a Pituitary Lesion. *J ECT*. 2018 Jun 26. doi: 10.1097/YCT.0000000000000516. [Epub ahead of print].
86. **Wilkinson ST**, Rosenheck R. Access to Outpatient Electroconvulsive Therapy at VA Medical Centers – Reply [Letter to the editor]. *J ECT*. 2018 Jun 12. doi: 10.1097/YCT.0000000000000511. [Epub ahead of print]
87. Katz RB, Toprak M, **Wilkinson ST**, Sanacora G, Ostroff R. Concurrent use of ketamine and monoamine oxidase inhibitors in the treatment of depression: A letter to the editor. *Gen Hosp Psychiatry*, 2018 Sep - Oct;54:62-64.
88. Roxas N, Ahuja C, Isom J, **Wilkinson ST**, Capurso N. A potential case of acute ketamine withdrawal: clinical implications for the treatment of refractory depression. *Am J Psychiatry*, 2021 Jul;178(7):588-591.
89. O'Brien B, **Wilkinson ST**, Mathew SJ. "An Update on Community Ketamine Practices," *Am J Psychiatry* (in press).
90. **Wilkinson ST**, Sanacora G. "At-home Ketamine; Still A Lot to Learn," *Journal of Affective Disorders*. 2022 Dec 1;318:150-151. doi: 10.1016/j.jad.2022.08.090. Epub 2022 Sep 5.